Carisma Therapeutics Inc. Cash Flow Conversion Efficiency
Carisma Therapeutics Inc. cash flow conversion efficiency. Based on the latest financial reports, Carisma Therapeutics Inc. (CARM) has a cash flow conversion efficiency ratio of -2.201x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.91 Million) by net assets ($-867.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Carisma Therapeutics Inc. (2011–2024)
Cash flow conversion efficiency of Carisma Therapeutics Inc. from 2011 to 2024. This chart illustrates how Carisma Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Carisma Therapeutics Inc. stock price for real-time trading data and today's change.
Carisma Therapeutics Inc. Cash Flow Conversion Ratio Explained
Carisma Therapeutics Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Carisma Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carisma Therapeutics Inc. ranked by their cash flow conversion efficiency. Also see CARM company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
STRATA Skin Sciences Inc
NASDAQ:SSKN
|
-0.082x |
|
Malvern International
LSE:MLVN
|
-0.476x |
|
Europlasma SA
PA:ALEUP
|
0.657x |
|
PHILION SE O.N.
F:PH6
|
N/A |
|
FAT Brands Inc
NASDAQ:FATBW
|
0.050x |
|
Chordate Medical Holding AB
ST:CMH
|
-0.514x |
|
Ukrproduct Group
LSE:UKR
|
0.227x |
|
Hamak Gold Ltd
LSE:HAMA
|
0.000x |
Annual Cash Flow Conversion Efficiency for Carisma Therapeutics Inc. (2011–2024)
The table below shows the annual cash flow conversion efficiency of Carisma Therapeutics Inc. from 2011 to 2024. Review CARM free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-27.91 Million | $-59.92 Million | 2.147x | +170.17% |
| 2023-12-31 | $26.53 Million | $-81.18 Million | -3.060x | -5869.38% |
| 2022-12-31 | $-142.67 Million | $-7.57 Million | 0.053x | +124.39% |
| 2021-12-31 | $171.71 Million | $-37.33 Million | -0.217x | -107.43% |
| 2020-12-31 | $-9.23 Million | $-27.01 Million | 2.927x | +108.32% |
| 2019-12-31 | $-26.70 Million | $-37.52 Million | 1.405x | +372.12% |
| 2018-12-31 | $44.21 Million | $-22.83 Million | -0.516x | +47.58% |
| 2017-12-31 | $18.03 Million | $-17.77 Million | -0.985x | -1553.09% |
| 2016-12-31 | $38.68 Million | $2.62 Million | 0.068x | +103.72% |
| 2015-12-31 | $18.94 Million | $-34.53 Million | -1.823x | -129.03% |
| 2014-12-31 | $36.83 Million | $-29.31 Million | -0.796x | +86.16% |
| 2013-12-31 | $2.35 Million | $-13.49 Million | -5.752x | -72.90% |
| 2012-12-31 | $5.74 Million | $-19.09 Million | -3.327x | -104.50% |
| 2011-12-31 | $-147.00K | $-10.87 Million | 73.939x | -- |
About Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced… Read more